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MaBACKGROUND Risk prediction in elderly patients is increasingly relevant due to longer life expectancy.
OBJECTIVES This study sought to examine whether electrocardiographic (ECG) changes provide prognostic
information incremental to current risk models and to the conventional risk factors.
METHODS In all, 6,991 participants from the Copenhagen Heart Study attending an examination at age $65 years
were included. ECG changes were deﬁned as Q waves, ST-segment depression, T-wave changes, ventricular conduction
defects, and left ventricular hypertrophy based on the Minnesota code. The primary endpoint was fatal cardiovascular
disease (CVD) event and the secondary was fatal or nonfatal CVD event. In our study, 2,236 fatal CVD and 3,849 fatal or
nonfatal CVD events occurred during a median of 11.9 and 9.8 years of follow-up.
RESULTS ECG changes were frequently present (30.6%) and associated with conventional risk factors. All ECG changes
except 1 univariably predicted both endpoints. Event rates of ECG changes versus no ECG changes were respectively
41.4% versus 27.8% and 64.6% versus 50.8%. When added to existing risk scores, ECG changes independently
increased the risk of both endpoints. Fatal CVD events: hazard ratio (HR): 1.33 (95% conﬁdence interval [CI]: 1.29 to 1.36;
p < 0.001) and fatal or nonfatal CVD events: HR: 1.21 (95% CI: 1.19 to 1.24; p < 0.001). When added to conventional risk
factors, continuous net reclassiﬁcation improvement was 42.3% (95% CI: 42.0 to 42.4; p < 0.001) for fatal and 29.2%
(95% CI: 28.4 to 29.2; p < 0.001) for fatal or nonfatal events. Categorical net reclassiﬁcation was 7.1% (95% CI: 6.7 to
9.0; p < 0.001) for fatal and 4.2% (95% CI: 3.5 to 5.6; p < 0.001) for fatal or nonfatal events.
CONCLUSIONS Simple assessment of the existence of ECG changes improves risk prediction in the general population of
persons age$65 years. (J Am Coll Cardiol 2014;64:898–906) © 2014 by the American College of Cardiology Foundation.B y 2050, 25% of persons alive in the Westernworld are expected to be $65 years (1). Thisdemographic transition will be a major socio-
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AB BR E V I A T I O N S
AND ACRONYM S
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ECG = electrocardiogram/
electrocardiographic
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899suitable in older persons, as they are derived from
populations of none or only few persons age $65
years (3,4). Moreover, conventional risk factors are
not as inﬂuential in the development of CVD in this
age group as they are in the middle-age population
(5), and consequently, other risk markers are
needed.SEE PAGE 907
HR = hazard ratio
ICD = International
Classiﬁcation of Diseases
IQR = interquartile range
NRI = net reclassiﬁcation indexElectrocardiographic (ECG) changes carry a large
potential of such a marker. Their prevalence increases
rapidly in this age group (6); they are easily assessed
in most clinical settings; and they are a marker of
direct pathology, representing at least some level of
subclinical, cardiac impairment. In addition, the past
50 years, a number of studies have shown that ECG
changes are strongly associated with future CVD in
persons who are not previously diagnosed with the
condition (7–12).
Although use of the ECG in risk prediction is not
currently recommended in asymptomatic individuals
(13), it may be very well suited for this purpose in
the subgroup of persons age $65 years. Therefore,
we hypothesized that risk prediction of persons
age $65 years would be improved by adding ECG
changes. To test this, we examined whether adding
ECG changes to the European Heart Score (3), the
Framingham Global Risk Score (14), and the con-
ventional risk factors would contribute with incre-
mental prognostic information and improve risk
prediction.Persons att
Persons ag
(not previo
n=14,223 /
n=2,092
n=12,698 /
n=1,515
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FIGURE 1 Participants Included in the Present Cohort of Persons Ag
For each examination, the total number of persons attending and the tot
present cohort. A person could only be included once in the present coMETHODS
STUDY COHORT. The Copenhagen City Heart
Study was initiated during a 2-year period
from 1976 to 1978. At that time, a random
sample of 19,329 mainly white Caucasians
living within a well-deﬁned area of the
inner Copenhagen City Boundary was
randomly selected and invited to participate
(participation rate: 74% [n ¼ 14,223]). In the
subsequent examinations, the surviving par-
ticipants were invited again, and the cohort
was supplemented with persons from the younger
strata (Figure 1). For the present purpose, only per-
sons who have attended an examination at an
age $65 years and were free from CVD at the time
of the examination were included. Persons with
missing ECG were excluded.
All subjects gave informed consent to participate,
and the Regional Ethical Committee for Medical
Research in Copenhagen approved the study.
CONVENTIONAL RISK FACTORS. Conventional risk
factors were deﬁned as risk factors from either the
European Heart Score or the Framingham Global Risk
Score, which include the following: increasing age;
systolic blood pressure; total cholesterol; male sex;
current smoking; and diabetes. They were assessed
as follows. Blood pressure was measured after 5 min
of rest using the left arm with a cuff adjusted to arm
circumferential. Smoking status was self-reported.
Total cholesterol was measured at all examinations,ending an examination /
e ≥ 65 years
usly included)
Total no. of persons age ≥ 65
years
91-1994 2001-2003
Follow-up
End 2011
10,135 /
=2,331
n=6,237 /
n=1,054
n=6,992 
Copenhagen City Heart Study
e $65 Years
al number of persons age $65 years are shown. The persons age $65 years were pooled in the
hort.
CENTRAL ILLUSTRATION Forest Plots of Different Risk Models, All With Information on ECG Changes With Regard to
Fatal and the Combination of Fatal or Nonfatal CVD in Persons Age $65 Years
The effect of electrocardiographic (ECG) changes when adjusted for estimates of calculated risks of either the European Heart Score model or
the Framingham Global Risk Score. Hazard ratios (HR) displayed: European Heart Score and Framingham Global Risk Score per 10% increase
in predicted risk by the corresponding model. Levels of signiﬁcance: *p < 0.05, **p < 0.01, and ***p < 0.001. CI ¼ conﬁdence interval;
CVD ¼ cardiovascular disease.
TABLE 1 Baseline Characteristics
No ECG Changes
(n ¼ 4,851)
ECG Changes
(n ¼ 2,140) p Value
Minor ECG
Changes
(n ¼ 624)
Intermediate
ECG Changes
(n ¼ 353)
Major ECG
Changes
(n ¼ 1,163) p Value
Conventional risk factors
Age, yrs 69.5  3.5 70.2  4.1 <0.001 69.9  3.7 70.4  4.0 70.3  4.4 <0.001
Males 1,893 (39.0) 986 (46.1) <0.001 276 (44.2) 125 (35.4) 585 (50.3) <0.001
Current smoking 2,232 (46.4) 1,017 (47.8) 0.28 293 (47.4) 174 (49.6) 550 (47.5) 0.63
Systolic BP, mm Hg 146.9  20.5 157.4  24.2 <0.001 154.1  22.0 154.6  22.8 160.1  25.5 <0.001
Diastolic BP, mm Hg 83.5  11.6 87.2  13.4 <0.001 85.9  12.6 86.6  12.3 88.1  14.2 <0.001
Total cholesterol, mmol/l 6.3  1.2 6.3  1.3 0.21 6.5  1.3 6.5  1.4 6.2  1.2 <0.001
Body mass index, kg/m2 26.0  4.3 26.2  4.3 0.25 27.0  4.5 26.1  4.4 25.8  4.2 <0.001
Diabetes mellitus 208 (4.4) 151 (7.2) <0.001 55 (9.0) 20 (5.8) 76 (6.7) <0.001
Resting heart rate, beats/min 73.3  13.2 75.3  14.0 <0.001 75.6  13.1 75.2  13.2 75.3  14.7 <0.001
Estimated risks using existing scores
SCORE risk model, % 13.1 (8.0–21.1) 18.3 (10.7–29.6) <0.001 16.8 (10.5–30.0) 17.4 (9.9–27.6) 19.5 (11.1–32.3) <0.001
Framingham Global Risk, % 25.9 (16.9–39.9) 33.4 (21.6–51.1) <0.001 33.7 (21.6–51.9) 32.4 (20.2–48.5) 33.9 (22.0–51.4) <0.001
ECG changes
Q waves
Present 161 (7.5) 53 (8.4) 60 (17.0) 48 (4.1)
Minor 81 (3.8) 53 (8.4) 10 (2.8) 18 (1.6)
Intermediate 62 (2.9) 50 (14.2) 12 (1.0)
Major 18 (0.8) 18 (1.6)
ST-segment depressions
Present 616 (28.8) 106 (17.0) 248 (70.3) 262 (22.5)
Minor 204 (9.5) 106 (17.0) 55 (15.6) 43 (3.7)
Intermediate 294 (13.7) 193 (54.7) 101 (8.7)
Major 118 (5.5) 118 (10.1)
T waves
Present 1,255 (58.6) 577 (92.5) 313 (88.7) 365 (31.4)
Minor 845 (39.4) 577 (92.5) 117 (33.1) 151 (13.0)
Intermediate 388 (18.1) 196 (55.5) 192 (16.5)
Major 22 (1.0) 22 (1.9)
Ventricular conduction defects 254 (11.9)
Left ventricular hypertrophy 850 (39.7)
Values are mean  SD, n (%), or median (interquartile range).
BP ¼ blood pressure; ECG ¼ electrocardiogram; SCORE ¼ Systematic Coronary Risk Evaluation.
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FIGURE 2 Kaplan-Meier Plots
Kaplan-Meier plots of proportion free of fatal cardiovascular disease (CVD) and proportion free of fatal or nonfatal CVD stratiﬁed by presence
and severity of electrocardiographic (ECG) changes, respectively.
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901whereas measurement of high-density lipoprotein
cholesterol was not available at the ﬁrst examination
and only measured on a subgroup of the persons at
the second examination. Diabetes mellitus was de-
ﬁned as plasma glucose concentration $11.1 mmol/l,
use of insulin, other antidiabetic medicine, or self-
reported disease (15,16). Resting heart rate was read
from the ECG.
KNOWN CVD. Known CVD was self-reported and
cross-validated with the highly validated Danish
National Board of Health’s National Patient Registry
using International Classiﬁcation of Diseases (ICD)-8
codes (before 1994): 410 to 414 (ischemic heart dis-
ease), 430 to 438 (stroke), and 440 to 441 and 444(peripheral atherosclerotic disease), or ICD-10 codes
(after 1994): I20 to I25 (ischemic heart disease), I46
(cardiac arrest), I50 (heart failure), I60 to I68 (stroke),
and I70 to -I72 and I74 (peripheral atherosclerotic
disease). However, because the National Patient
Registry was not established until 1977, validation
in the ﬁrst and second examination was done by
reviewing medical ﬁles at general practitioners.
ECG. At inclusion, a 12-lead ECG was obtained on all
individuals and coded according to the Minnesota
Code Classiﬁcation system (17,18). Two independent
reviewers reviewed all, and in cases of disagreement,
a third reviewer adjudicated. ECG changes were
deﬁned as Q waves (1.1.x to 1.3.x), ST-segment
Q waves HR (95% CI) HR (95% CI)
Fatal CVD
Univariable Analysis of ECG Changes
Fatal or non-fatal CVD
No Q waves (reference) 1.00 1.00
1.00
1.00
1.00
1.00
1.00
2.07 (1.78-2.40)***
1.32 (1.21-1.45)***
1.57(1.47-1.68)***
1.42(1.27-1.58)***
1.57(1.37-1.80)***
1.66(1.53-1.80)***
1.00
1.00
1.00
1.00
1.00
1.80(1.65-1.96)***
1.81(1.59-2.07)***
1.59(1.33-1.91)***
1.85(1.67-2.06)***
1 2 4 8 1 85.651.41 2 42.82
Hazard Ratio Hazard Ratio
1.67(1.30-2.15)*** 1.70(1.40-2.07)***
1.78(1.61-1.97)***
1.57(1.46-1.70)***
1.34(1.22-1.47)***
2.16(1.91-2.45)***
5.89(3.83-9.06)***
1.63(1.24-2.13)***
1.53(1.28-1.83)***
1.61(1.40-1.86)***
3.17(2.58-3.88)***
3.97(2.25-7.01)***
1.52(1.10-2.10)*
1.95(1.71-2.21)***
1.78(1.43-2.21)***
1.87(1.70-2.06)***
1.92(1.57-2.34)***
1.47(1.31-1.65)***
1.64(1.46-1.84)***
2.42(2.07-2.83)***
8.19(5.00-13.43)**
1.66(1.39-1.99)***
3.48(2.73-4.45)***
1.71(1.23-2.38)**
1.35(0.86-2.11)
3.44(1.64-7.23)**
No ST depressions (reference)
Minor ST depressions 
Minor T wave changes 
Minor ECG changes
No T wave changes (reference) 
No conduction defects (reference) 
No hypertrophy (reference) 
No ECG changes (reference) 
ECG changes
Hypertrophy
Conduction defects
T wave changes 
ST depressions
Q waves 
Minor Q waves 
Intermediate Q waves 
Intermediate ST depressions 
Intermediate T wave changes
Intermediate ECG changes
Major Q waves 
Major ST depressions 
Major T wave changes
Major ECG changes
ST depressions
T wave changes
Ventricular conduction defects
Left ventricular hypertrophy
Overall ECG changes
FIGURE 3 Forest Plots of Univariable Analyses of ECG Changes
Univariable analyses of the associations of each ECG change and the combined ECG changes with the endpoints of fatal CVD and the combination of fatal or nonfatal
CVD. Levels of signiﬁcance: *p < 0.05, **p < 0.01, and ***p < 0.001. CI ¼ conﬁdence interval; HR ¼ hazard ratio; other abbreviations as in Figure 2.
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902depressions (4.1 to 4.3), T-wave changes (5.1 to 5.3),
left ventricular conduction defects (7.1.x and 7.2.x),
and left ventricular hypertrophy (3.1 and 3.2). If
present, the 2 latter changes were regarded as
major ECG changes. In case >1 ECG change was
coded, the lowest value (i.e., the largest ECG change)
determined the class.
ENDPOINTS. Two equal endpoints were used to
reﬂect both European and U.S. guidelines: fatal CVD
and the combination of fatal or nonfatal CVD. Addi-
tionally, all-cause mortality was used in supple-
mental analyses. The Danish National Board of
Health’s National Patient Registry and Register of
Cause of Death was used to obtain the CVD events
deﬁned as death or admission with the above-
mentioned ICD-8 and ICD-10 codes.
STATISTICAL ANALYSES. Absolute 10-year risk of
fatal CVD and 10-year risk of the combination of
fatal or nonfatal CVD as estimated by the European
Heart Score and the Framingham Global Risk Score,respectively, were calculated on all participants using
previously published formulas (3,14). Missing values
of high-density lipoprotein cholesterol for calculation
of Framingham Global Risk Score was set to the mean
value of the remaining participants.
Multivariable analyses shown in the Central
Illustration were performed using Cox proportional
hazards regression models using all available follow-
up and with adjustments for European Heart Score,
Framingham Global Risk Score (with corresponding
endpoints), or conventional risk factors with both
endpoints (fatal CVD and the combined endpoint of
fatal or nonfatal CVD). Non-CVD mortality also was
considered as a competing risk, the results of which
are shown in Online Figure 1.
MODEL VALIDATION AND DISCRIMINATION. Cox
models were internally validated using boot-
strapping with 10,000 samples, and the estimates
were corrected for optimism. Conﬁdence intervals
were calculated using bias-corrected and accelerated
TABLE 2 Comparison Between Models With and Without ECG Changes and Resting Heart Rate
Fatal CVD Events Fatal or Nonfatal CVD Events
C-Index
(95% CI)
Continuous
NRI (%)
(95% CI)
Categorical
NRI (%)
(95% CI)
C-Index
(95% CI)
Continuous
NRI (%)
(95% CI)
Categorical
NRI (%)
(95% CI)
Conventional risk factors 0.705
(0.687-0.723)
0.651
(0.639-0.663)
Conventional risk factors and
Q waves
As present or not 0.709
(0.691-0.727)*
5.3
(-0.02 to 12.9)
1.9
(0.7-3.1)†
0.655
(0.643-0.667)†
3.9
(-1.6 to 9.5)
0.7
(-0.2 to 1.8)
With increasing severity 0.710
(0.692-0.727)*
6.3
(-0.01 to 14.0)
2.1
(0.9-3.3)‡
0.655
(0.643-0.667)†
5.3
(-0.3 to 10.8)
0.9
(0.0-1.9)*
ST-segment depressions
As present or not 0.714
(0.697-0.732)‡
18.0
(10.4-25.6)‡
3.1
(0.7-5.4)*
0.660
(0.648-0.672)‡
14.7
(9.1-20.3)‡
2.2
(0.4-4.1)*
With increasing severity 0.717
(0.699-0.734)‡
18.5
(10.8-26.5)‡
3.5
(1.1-6.5)†
0.661
(0.649-0.673)‡
15.2
(9.7-20.8)‡
2.3
(0.5-4.0)*
T-wave changes
As present or not 0.716
(0.699-0.734)‡
29.2
(21.5-36.8)‡
5.4
(2.2-8.6)†
0.658
(0.647-0.670)‡
20.3
(14.7-25.9)‡
2.7
(0.6-4.8)*
With increasing severity 0.720
(0.702-0.732)‡
29.3
(21.6-36.9)‡
5.0
(1.8-8.3)†
0.662
(0.651-0.674)‡
20.2
(14.6-25.8)‡
3.3
(1.3-5.4)†
Ventricular conduction defect 0.708
(0.690-0.726)
2.8
(-4.9-10.4)
1.1
(0.1-2.1)*
0.655
(0.643-0.667)†
5.5
(-0.1 to 11.1)
0.0
(-1.1 to 1.2)
Left ventricular hypertrophy 0.706
(0.688-0.724)
12.1
(4.5-19.8)†
2.7
(1.0-4.4)†
0.651
(0.639-0.663)
6.7
(1.1-12.3)*
-1.1
(-2.3 to 0.1)
Resting heart rate 0.709
(0.691-0.727)†
14.1
(6.4-21.7)‡
0.9
(-1.8 to 3.7)
0.652
(0.640-0.664)
7.3
(1.8-12.9)*
-0.2
(-1.4 to 1.0)
ECG changes
As present or not 0.719
(0.702-0.737)‡
42.3
(34.7-50.0)‡
7.1
(3.6-10.6)‡
0.660
(0.648-0.672)‡
29.1
(23.6-34.7)‡
3.8
(1.4-6.3)†
With increasing severity 0.719
(0.702-0.736)‡
42.3
(34.7-50.0)‡
7.2
(3.7-10.7)‡
0.660
(0.648-0.671)‡
29.2
(23.7-34.8)‡
4.2
(1.8-6.7)‡
ECG changes and resting heart rate
As present or not 0.722
(0.705-0.740)‡
35.6
(28.0-43.3)‡
6.7
(3.0-10.3)‡
0.661
(0.649-0.672)‡
29.9
(24.3-34.5)‡
3.5
(1.0-6.0)†
With increasing severity 0.722
(0.705-0.740)‡
34.8
(27.3-42.5)‡
6.5
(2.9-10.1)‡
0.661
(0.649-0.673)‡
29.5
(24.0-35.1)‡
3.5
(0.9-5.9)†
Levels of signiﬁcance: *p < 0.05, †p < 0.01, and ‡p < 0.001.
CI ¼ conﬁdence interval; CVD ¼ cardiovascular disease; ECG ¼ electrocardiogram; NRI ¼ net reclassiﬁcation index.
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903bootstrapping. Cox model discrimination was as-
sessed using the C-statistics and categorical and
continuous net reclassiﬁcation index (NRI). These
statistics require a binary response, so the persons
with <10 years of follow-up were excluded. Adding
all ECG changes as present or not was marginally
better judged by the clinically relevant NRI. For
that reason and for the sake of simplicity, the
equations presented for calculating absolute risks
are based on these models. Also, they were used for
creating risk categories for categorical NRI for both
endpoints.
All statistical calculations were made using R
for Mac (version 2.15.3, R Project for Statistical
Computing, Vienna University of Economics and
Business Administration, Wien, Austria).RESULTS
In all, 6,991 persons, age $65 years and without
known CVD, were identiﬁed from the 4 examina-
tions in the Copenhagen City Heart Study (Figure 1).
For the additional endpoint of all-cause mortality,
follow-up was available until April 23, 2013. There
were no persons lost to follow-up, and the median
follow-up time was 11.9 years (interquartile range
[IQR]: 8.2 to 18.1, range 0.02 to 35.5) for fatal CVD
and 9.8 years (IQR: 5.7 to 15.9, range 0.01 to 35.4)
for the combination of fatal or nonfatal CVD. During
follow-up, 2,236 persons reached the endpoint of
fatal CVD, and 3,849 persons reached the combined
endpoint of fatal or nonfatal CVD, yielding event
rates of ECG changes versus no ECG changes of
TABLE 3 Model Validation
Conventional
Risk Factors
Conventional Risk
Factors and ECG Changes p Value
Fatal CVD events
C-index 0.705 (0.703-0.707) 0.719 (0.717-0.721)
Adjusted for optimism 0.706 0.720 <0.001
Continuous NRI, % 42.3 (42.0-42.4)
Adjusted for optimism 42.3 <0.001
Categorical NRI, %* 7.1 (6.7-9.0)
Adjusted for optimism 8.6 <0.001
Fatal or nonfatal CVD events
C-index 0.651 (0.649-0.653) 0.660 (0.658-0.662)
Adjusted for optimism 0.652 0.660 <0.001
Continuous NRI, % 29.2 (28.4-29.2)
Adjusted for optimism 29.2 <0.001
Categorical NRI (%)† 4.2 (3.5-5.6)
Adjusted for optimism 4.7 <0.001
Parenthetical values are 95% CI. Risk categories are based on tertiles of predicted risks using models with ECG
changes as present or not. Optimism estimates are obtained by bootstrapping 10,000 samples and CI by bias-
corrected and accelerated bootstrapping of 10,000 samples. *Risk categories: low risk: <8.9%; intermediate
risk: 8.9% to 14.9%; high risk: >14.9%. †Risk categories: low risk: <25.9%; intermediate risk: 25.9% to 36.6%;
high risk: >36.6%.
Abbreviations as in Tables 1 and 2.
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90441.4% versus 27.8% and 64.6% versus 50.8%,
respectively. For the additional endpoint of all-
cause mortality, median follow-up was 11.9 years
(IQR: 8.2 to 18.7, range 0.02 to 36.8), 5,626 eventsTABLE 4 Calculating 10-Year Risk of Fatal CVD and of Fatal or Nonfa
Step 1. Calculate I using regression coefﬁcients.
I ¼ B1  Age in yearsþ
B2  Systolic blood pressure ðmm HgÞþ
B3  Current smoking ð1 if “yes;” 0 if “no”Þþ
B4  Diabetes ð1 if “yes;” 0 if “no”Þþ
B5  Total cholesterol ðmmol=lÞþ
B6  Sex ð1 for man; 0 for womanÞþ
B7  ECG changes ð1 if present; 0 if notÞ
Step 2. Calculate estimated risks.
Risk of fatal CVD ¼ 1 0:8791 eI8:4573
Risk of fatal or nonfatal CVD ¼ 1 0:6811 eI6:8311
Case.
A 70-year-old woman, current smoker, with a systolic blood pressure of 14
and ECG changes
Risk of fatal CVD
I ¼ 70 0:0891þ 140 0:0101þ 1 0:4533þ 0 0:5570þ 5:1 0:033
Risk of fatal CVD ¼ 1 0:8791e 8:68798:4573 ¼ 15%
Risk of fatal or nonfatal CVD
I ¼ 70 0:0752þ 140 0:0072þ 1 0:3424þ 0 0:5738þ 5:1 0:017
Risk of fatal or nonfatal CVD ¼ 1 0:6811e7:01116:8311 ¼ 37%
Abbreviations as in Tables 1 and 2.occurred with event rates of 87.9% (ECG changes)
versus 71.2% (no ECG changes). The baseline char-
acteristics of the study population are shown in
Table 1.
UNADJUSTED ANALYSES. ECG changes were found
in 30.6% of the participants at baseline. The distri-
bution of Q waves, ST-segment depressions, T-wave
changes, left ventricular conduction defects, and
left ventricular hypertrophy in the combined ECG
changes are shown in Table 1. Kaplan-Meier curves
with age as the underlying time scale are shown in
Figure 2 and Online Figure 2. ECG changes were
signiﬁcantly associated with both endpoints. Strati-
fying by sex showed similar results. Figure 3 and
Online Figure 3 show univariable associations of ECG
changes with fatal CVD, the combination of fatal
and nonfatal CVD events, and the additional endpoint
of all-cause mortality.
ADJUSTED ANALYSES. ECG changes remained sig-
niﬁcantly associated with both endpoints when
included in a model with European Heart Score and
Framingham Global Risk Score, respectively (Central
Illustration). They remained signiﬁcantly associated
with both endpoints when included in a model
with all conventional risk factors. Though less pro-
nounced, the results were similar with the additionaltal CVD
Regression coefﬁcients for calculatingI
Fatal CVD Fatal or nonfatal CVD
B1 ¼ 0.0891
B2 ¼ 0.0101
B3 ¼ 0.4533
B4 ¼ 0.5570
B5 ¼ 0.0337
B6 ¼ 0.4836
B7 ¼ 0.4117
B1 ¼ 0.0752
B2 ¼ 0.0072
B3 ¼ 0.3424
B4 ¼ 0.5738
B5 ¼ 0.0172
B6 ¼ 0.3728
B7 ¼ 0.3090
0 mm Hg, a total cholesterol of 5.1 mmol/l, no history of diabetes,
7þ 0 0:4836þ 1 0:4117 ¼ 8:6879
2þ 0 0:3728þ 1 0:3090 ¼ 7:0111
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Adjusting for resting heart rate—that was also
evaluated as a possible variable in the ﬁnal model—
and examination number in the above-mentioned
models did not change the results. The same was the
case when stratifying by sex. Also, no interactions
were found between ECG changes and examination
number on the risk of reaching the endpoints. Testing
for interactions with age groups (<75 years, 75 to
84 years, and >85 years), and ECG changes showed
a signiﬁcant interaction of the 75 to 84 years age
group with ECG changes for both endpoints.
COMPARING 10-YEAR RISK MODELS WITH AND
WITHOUT ECG CHANGES. In all, 4,923 persons
with $10 years of follow-up for the endpoint of
fatal CVD (837 events) and 5,418 persons with
$10 years of follow-up for the combined endpoint of
fatal or nonfatal CVD (2,092 events) were found. For
the additional endpoint of all-cause mortality, this
number was 6,907 persons (2,225 events). C-index
and categorical and continuous NRI for adding each
ECG change and resting heart rate to the conven-
tional risk factors are found in Table 2 and Online
Table 1. It is apparent, that though adding resting
heart rate to the model with the conventional risk
factors and ECG changes improved the C-index,
the models without the resting heart rate had su-
perior performance judged by the clinically relevant
NRI. For this reason, the models with the conven-
tional risk factors and the ECG changes were chosen
as the ﬁnal models. The results of the statistical
tests for these models’ discrimination based on
10,000 bootstrap samples are shown in Table 3 and
Online Table 2.
DISCUSSION
In this study, we have shown that CVD risk estima-
tion of persons age $65 years can be improved by
adding ECG changes to the conventional risk factors.
Adding ECG changes as present or not is simplest
and performed equally well with adding ECG
changes with increasing severity and, therefore, was
chosen as the most appropriate approach. Informa-
tion needed to calculate predicted risks by this
model is found in Table 4. Estimation of all-cause
mortality was only marginally improved by adding
ECG changes.
PREVIOUS EVIDENCE OF USE OF THE ECG IN
RISK PREDICTION. The U.S. Preventive Services
Task Force has recommended against use of routine
ECG as a screening procedure based on a lack of evi-
dence of clinical beneﬁt (13). The task force, however,
did request studies on how addition of ECG toconventional risk factors affects reclassiﬁcation. A
study by Auer et al. (19) recently examined the effects
of major and minor ECG changes added to the con-
ventional risk factors in persons age $65 years and
found a correct reclassiﬁcation on the endpoint of
coronary heart disease in 7.4% of their population.
The present study contributes with longer follow-up
and expands the scope by providing means to pre-
dicting CVD in general. Additionally, as stated by the
investigators, use of minor and major ECG abnor-
malities is hampered by the complexity of detailed
ECG interpretation — a task not easily performed in
daily clinical practice. However, just looking for the
most well-known ECG changes is simpler and does
not require careful division of changes into categories
of severity.
CLINICAL IMPLICATIONS: A NEW ERA IN RISK
PREDICTION? The only way of estimating indi-
viduals’ absolute risks of developing CVD is by
extrapolating risks from the former generations.
Certainly, this is not the optimal solution as changes
in absolute risks are affected by time-speciﬁc factors,
such as contemporary lifestyle habits and health be-
haviors. The implication of this is that risk estimation
should be constantly developing as an adaptation to
the overall demographics in the society. The ongoing
transition implies that not only does the proportion
of the population of persons age $65 years continue
to increase, it also gets older with a growth rate twice
as high of persons $80 years as that of persons
$60 years (1). In connection with this development,
the task of primary prevention will no longer only be
limited to the current middle-age population, which
marks a broadening of focus that will require new
approaches to enable efﬁcient CVD risk estimation
across all ages.
STUDY LIMITATIONS. The study is strong in that we
have a well-described, randomly collected population
with long-term follow-up. Using a cohort pooled
from examinations performed during a 25-year period
is a disadvantage, as it yields large variation in the
follow-up period. However, as absolute risks are not
stable over time for persons with the same risk factors,
using a pooled cohort takes into account this variation
caused by changes in lifestyle and health behavior
during the 25-year period. Furthermore, we found
no interactions between ECG changes and examina-
tion attended on the risk of reaching either of the
endpoints.
Digital coding of ECG is increasingly used and
serves as a valuable assistant in the daily clinical
practice and may even be superior to visual assess-
ments (20). However, we did not have access to
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Current risk assessment tools were not designed for
speciﬁc application to people $65 years, in whom
other factors may have better predictive value.
Among these are electrocardiographic abnormalities
recorded at rest.
TRANSLATIONAL OUTLOOK: Additional research
is needed to validate other factors that might identify
older individuals who might beneﬁt from speciﬁc
interventions to reduce their risk of cardiovascular
events.
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906digital encodings and could not examine the useful-
ness of digitally coded ECG changes in relation to
improving risk prediction.
CONCLUSIONS
Based on these results, we have shown that CVD risk
prediction in persons age $65 years is improved
signiﬁcantly by adding ECG changes to the conven-
tional risk factors.
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